Associate Member St. Jude Children’s Research Hospital Memphis, Tennessee, United States
Session Description: Tumor mutational burden (TMB) is a biomarker that can predict response to immunotherapy. Many laboratories are offering TMB testing, but there is variation in how TMB is calculated, reported, and interpreted among laboratories. While TMB standardization efforts are underway, no published guidance for TMB validation and reporting is currently available. To address these challenges, the Association for Molecular Pathology has convened a multidisciplinary collaborative working group with representation from the American Society of Clinical Oncology, College of American Pathologists, and Society for the Immunotherapy of Cancer to review the laboratory practices surrounding TMB and develop recommendations for the analytical validation and reporting of TMB testing..
Learning Objectives:
Discuss literature review findings and new draft recommendations for TMB assay validation and test reporting.
Discuss new draft recommendations and their impact on clinical practice.
